[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Get the name of the company here >>>
James  Cullen net worth and biography

James Cullen Biography and Net Worth

Director of Avinger
James G. Cullen has served as a member of our board of directors since December 2014, as our Lead Independent Director since January 2015 and as our Non-Executive Chairman since December 2017. During the last five years, Mr. Cullen has held board and committee positions with various companies. Mr. Cullen is currently a director of Keysight Technologies, which was spun out of Agilent Technologies, where he was previously a director. Mr. Cullen previously served as a director and chairman of the audit committee of Johnson & Johnson and as a director and member of the investment and finance committees of Prudential Financial. From 1993 to 2000, Mr. Cullen was President, Vice Chairman and Chief Operating Officer of Bell Atlantic Corporation (now Verizon). From 1989 to 1993, he was President and Chief Executive Officer of Bell Atlantic-New Jersey. Mr. Cullen holds a B.A. in Economics from Rutgers University and an M.S. in Management Science from the Massachusetts Institute of Technology.

What is James Cullen's net worth?

The estimated net worth of James Cullen is at least $166,368.16 as of May 31st, 2019. Mr. Cullen owns 25,361 shares of Avinger stock worth more than $166,368 as of September 28th. This net worth estimate does not reflect any other assets that Mr. Cullen may own. Learn More about James Cullen's net worth.

How do I contact James Cullen?

The corporate mailing address for Mr. Cullen and other Avinger executives is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. Avinger can also be reached via phone at (650) 241-7900 and via email at [email protected]. Learn More on James Cullen's contact information.

Has James Cullen been buying or selling shares of Avinger?

James Cullen has not been actively trading shares of Avinger within the last three months. Most recently, James Cullen sold 12 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $8.55, for a transaction totalling $102.60. Learn More on James Cullen's trading history.

Are insiders buying or selling shares of Avinger?

In the last year, insiders at the medical device company sold shares 1 times. They sold a total of 14 shares worth more than $170.10. The most recent insider tranaction occured on March, 23rd when VP Nabeel Paul Subainati sold 14 shares worth more than $170.10. Insiders at Avinger own 7.1% of the company. Learn More about insider trades at Avinger.

Information on this page was last updated on 3/23/2023.

James Cullen Insider Trading History at Avinger

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2021Sell12$8.55$102.60View SEC Filing Icon  
11/24/2021Sell2$9.30$18.60View SEC Filing Icon  
2/4/2015Sell153$195.00$29,835.00View SEC Filing Icon  
See Full Table

James Cullen Buying and Selling Activity at Avinger

This chart shows James Cullen's buying and selling at Avinger by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Avinger Company Overview

Avinger logo
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $6.56
Low: $6.26
High: $6.89

50 Day Range

MA: $9.95
Low: $4.13
High: $69.45

2 Week Range

Now: $6.56
Low: $4.14
High: $24.30


164,532 shs

Average Volume

658,302 shs

Market Capitalization

$4.72 million

P/E Ratio


Dividend Yield